Clinical Trials Logo

Clinical Trial Summary

Skin photoaging or skin photodamage were terms used to describe the change in the structure, function and appearance of skin caused by prolonged and repeated exposure to sunlight or other ultraviolet light sources. The visible effects of skin photodamage were fine lines, skin sagging, skin roughness, liver spots and also the appearance of red patches made up of thin red vessels (called telangiectasia). More and more people were presenting to doctors with concerns about skin photodamage and the demand for corrective procedures was increasing. Metvix photodynamic therapy (Metvix PDT) is a procedure currently marketed in several countries in Europe (including the United Kingdom [UK] and Spain) and in Australia, for the treatment of benign forms of skin cancer (example, actinic keratosis). The aim of the study was to assess whether Metvix PDT would be effective in correcting the effects related to photodamage and whether it would be well tolerated.


Clinical Trial Description

Different application times of the study treatment were being investigated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00437320
Study type Interventional
Source Galderma R&D
Contact
Status Completed
Phase Phase 2
Start date April 18, 2007
Completion date September 1, 2008

See also
  Status Clinical Trial Phase
Recruiting NCT02889159 - Immunologic Profile of Chronically Photodamaged Skin Phase 4
Completed NCT00857610 - Retinol-induced Dermatitis in Aged Skin